Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
92%
Adverse Event
77%
Aripiprazole
64%
Headache
46%
Remission
45%
Typical Antipsychotic
45%
Polypharmacy
43%
Clozapine
42%
Recurrent Disease
40%
Symptom
40%
Treatment-Resistant Schizophrenia
40%
Major Depression
40%
Random Effects Model
34%
Adverse Drug Reaction
30%
Placebo
24%
Paliperidone
24%
Risperidone
24%
Cohort Study
23%
Pharmacovigilance
22%
Diazepam
22%
Observational Study
21%
Disproportionality Analysis
21%
Depression
20%
Febrile Neutropenia
20%
Aspartate Aminotransferase
20%
Cisplatin
20%
Recurrence Risk
20%
Antidepressant
20%
Bipolar Mania
20%
Disease
20%
Lamictal
20%
Bipolar I Disorder
20%
Olanzapine
20%
Drug Administration
20%
Hemoglobin A1c
20%
Fluorouracil
20%
High Density Lipoprotein Cholesterol
20%
Population Study
20%
Asenapine
20%
Monotherapy
20%
Controlled Release
20%
Randomized Controlled Trial
20%
Delirium
20%
FDA Adverse Event Reporting System
20%
Hypnotic
20%
Randomized Clinical Trial
20%
Negative Syndrome
20%
Immune Checkpoint Inhibitor
20%
Acute Psychosis
20%
Xanomeline
20%
Keyphrases
Meta-analysis
41%
Major Depressive Disorder
41%
Newer Antidepressants
40%
Systematic Meta-analysis
40%
Left DLPFC
33%
Japan
31%
Pairwise Meta-analysis
29%
Confidence Interval
27%
Antidepressants
26%
Antipsychotics
23%
Vortioxetine
22%
Patients with Schizophrenia
20%
Febrile Neutropenia
20%
Older People
20%
Subjective Survey
20%
Bipolar Mania
20%
Long-acting Injectable Aripiprazole
20%
Neutrophil-lymphocyte Ratio
20%
Long-acting Injection
20%
Muscle Injection
20%
Lamotrigine
20%
Enrichment Design
20%
Japanese Adverse Drug Event Report (JADER)
20%
5-fluorouracil (5-FU)
20%
Clozapine
20%
Deltoid Injection
20%
Cisplatin
20%
Trends Survey
20%
Monotherapy
20%
Treatment-resistant Schizophrenia
20%
Antipsychotic Polypharmacy
20%
Work Outcomes
20%
Mirror-image Study
20%
Intermittent theta Burst Stimulation (iTBS)
20%
Japanese Adults
20%
FAERS Database
20%
Trospium
20%
Xanomeline
20%
Standardized Mean Difference
19%
Risk Ratio
18%
Japanese Patients
16%
Depressive Symptoms
15%
Placebo
15%
High-dose Antipsychotics
15%
Pharmacist-led
13%
Randomized Placebo-controlled Trial
12%
Symptom Scale
12%
Cariprazine
12%
Gluteal Injection
12%
Clozapine Discontinuation
12%
Neuroscience
Meta-Analysis
100%
Major Depressive Disorder
46%
Dorsolateral Prefrontal Cortex
46%
Clozapine
40%
Treatment-Resistant Schizophrenia
40%
Antidepressant
40%
Placebo
25%
Dementia Praecox
22%
Benzodiazepine Receptor
20%
Receptor Agonists
20%
Suvorexant
20%
Mixed Anxiety and Depression
20%
Asenapine
20%
Headache
16%
Typical Antipsychotic
15%
Occipital Lobe
13%
Prefrontal Cortex
13%
Depression
10%
Negative Syndrome
10%
Adverse Effect
9%
Antipsychotic
7%
Treatment of Depression
6%
Randomized Controlled Trial
6%
Schizoaffective Disorder
6%
Positive Syndrome
6%
